No. No label and no trial supports taking semaglutide and tirzepatide together, in the same week, or on alternating weeks. The Zepbound label says not to use it with any GLP-1 receptor agonist, and semaglutide is one. Both drugs act on the same receptor. Both stay in the body for days, so a week apart is not really apart. If you want to switch from one to the other, ask your prescriber. That is their call, not a schedule you build yourself. New to the drug? Read our tirzepatide guide first.
Key takeaways
- The Zepbound label's Limitations of Use state that coadministration with other tirzepatide products or with any GLP-1 receptor agonist is not recommended.
- Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist, so this applies to it.
- Tirzepatide's half-life is about 5 days and it reaches steady state after 4 weeks; a dose taken this week is still active next week.
- The tirzepatide label requires at least 72 hours between two tirzepatide doses and says never to take two within 3 days.
- No SURMOUNT or SURPASS trial tested the two drugs together; SURMOUNT-5 tested them against each other, one drug per person.
Can you take semaglutide and tirzepatide together?
Not according to the label. The Zepbound prescribing information lists this under Limitations of Use: "Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." That sentence covers semaglutide, which is a GLP-1 receptor agonist. It also covers taking two tirzepatide products at once, such as a compounded vial plus a Zepbound pen.
The reason is not mysterious. Both drugs push on the same GLP-1 receptor. Tirzepatide also pushes on the GIP receptor. Stacking them means more of the same signal with no trial to say what that does to side effects or safety. Every efficacy number for these drugs comes from trials of one drug at a time.
Can you take semaglutide and tirzepatide in the same week?
A week apart is not a workaround. Tirzepatide's elimination half-life is about 5 days, and it takes 4 weeks of weekly dosing to reach a steady level. That means the tirzepatide you injected on Monday is still working the following Monday. If you inject semaglutide on Thursday, you have both drugs active at once. The same logic applies to alternating weeks. From the receptor's point of view, "same week," "same day" and "alternating weeks" are all coadministration.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →| Question | What the sources say |
|---|---|
| Same day? | Coadministration with any GLP-1 receptor agonist is not recommended (Zepbound label). |
| Same week? | Still overlap; tirzepatide half-life is about 5 days, so it is active all week. |
| Alternating weeks? | Still overlap; steady state takes 4 weeks, and each drug persists for days after a dose. |
| Mixed in one syringe? | No label, pharmacy standard or trial supports mixing the two. |
| Two tirzepatide doses close together? | Never within 3 days; at least 72 hours apart if the day is changed. |
| Switching from one to the other? | Prescriber decision; the tirzepatide label starts everyone at 2.5 mg once weekly for 4 weeks. |
Source: Zepbound and Mounjaro prescribing information (DailyMed), Limitations of Use, Dosage and Administration, Clinical Pharmacology.
Can you mix semaglutide and tirzepatide?
No. Mixing means drawing both into one syringe or combining vials. There is no label, no compounding standard and no trial that supports it. Mixing also destroys your ability to know the dose of either drug. If someone is selling a vial that claims to contain both, that is a product with no evidence behind it. The FDA's page on unapproved GLP-1 drugs warns about products from unverified sources that may not contain what they claim.
What happens if you take both?
There is no trial that measured this, so we will not invent an outcome. What the labels do tell you is what each drug does alone. The most common tirzepatide reactions are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity, burping, hair loss and reflux. The label also warns about pancreatitis, gallbladder disease, kidney injury from fluid loss, and hypoglycemia in people who also take insulin or a sulfonylurea. If you took both drugs by mistake, call your prescriber or pharmacist that day, tell them the doses and the times, and follow their instructions. Do not take another dose of either to "even it out."
Why would anyone want to combine them?
Usually one of three reasons. Some people have leftover semaglutide when they start tirzepatide. Some hope for more weight loss. Some are trying to smooth a switch. For the first, the leftover drug is not a reason to overlap; ask your prescriber what to do with it. For the second, the head-to-head trial already answers the question: in SURMOUNT-5, tirzepatide alone produced 20.2% mean weight loss versus 13.7% for semaglutide alone at 72 weeks. No trial shows that adding the weaker drug to the stronger one adds anything. For the third, the switch belongs to your prescriber.
| SURMOUNT-5 (72 weeks, one drug per person) | Tirzepatide | Semaglutide |
|---|---|---|
| Mean change in body weight | -20.2% | -13.7% |
Source: SURMOUNT-5, Aronne et al., NEJM 2025.
Switching from semaglutide to tirzepatide, or back
Switching is common, but it is a prescriber decision, and the labels do not give a washout number. What the tirzepatide label does say is where to start: 2.5 mg once weekly for 4 weeks, then 2.5 mg steps after at least 4 weeks on each dose, up to 15 mg. The 2.5 mg starting dose is for tolerability, and the label does not offer a shortcut for people coming from another drug. Your prescriber decides when your last semaglutide dose is and when your first tirzepatide dose is. The tirzepatide label rules on spacing apply once you are on it: never two tirzepatide doses within 3 days, and at least 72 hours between doses if you change your day.
What this means for compounded tirzepatide
All of this applies to compounded products too. Compounded semaglutide and compounded tirzepatide are not FDA approved and are not interchangeable with Wegovy, Ozempic, Zepbound or Mounjaro. A compounded vial of one plus a compounded vial of the other is still two GLP-1 receptor agonists at once. At FormBlends, prescriptions are written by independent, state-licensed clinicians of Recess MD LLC, and a switch between the two compounded drugs goes through them. A licensed provider decides whether either is appropriate for you. See pricing for both, or begin the assessment.
Frequently Asked Questions
Can you take semaglutide and tirzepatide together?
No. The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended, and semaglutide is one. No trial has tested the two drugs together.
Can you take semaglutide and tirzepatide in the same week?
No. Tirzepatide has a half-life of about 5 days and stays active all week, so a dose of semaglutide a few days later overlaps with it. The label's warning about coadministration still applies.
Can you take semaglutide and tirzepatide at the same time?
No. Same time, same day and same week all mean both drugs are active together. If you took both by mistake, call your prescriber or pharmacist that day and do not take another dose of either.
Can you mix semaglutide and tirzepatide in one syringe?
No. There is no label, compounding standard or trial that supports mixing them, and you would lose track of the dose of each. Products that claim to contain both have no evidence behind them.
How do I switch from semaglutide to tirzepatide?
Through your prescriber. The labels do not give a washout period. The tirzepatide label starts everyone at 2.5 mg once weekly for 4 weeks, and your prescriber sets the date of your last semaglutide dose and your first tirzepatide dose.
Sources
- Zepbound (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Mounjaro (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Zepbound US prescribing information (PDF), Eli Lilly and Company, revised 08/2026.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), Aronne et al., New England Journal of Medicine, 2025.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration.
Next steps
For how the two drugs compare one at a time, read semaglutide vs tirzepatide. For how long the drug lingers, see how long tirzepatide stays in your system, and for the spacing rules, the tirzepatide dosage chart. Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician before you switch or combine anything. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →